Guillain-Barré Syndrome in a Patient with a Renal Carcinoma – a Case Report

Česká verze

Authors: L. Večeřa ¹; J. Bednařík1 ^,2
Authors place of work: Neurologická klinika LF MU a FN Brno ¹; Středoevropský technologický institut (CEITEC), MU, Brno ²
Published in the journal: Cesk Slov Neurol N 2012; 75/108(1): 84-87
Category: Kazuistika

Summary

Guillain-Barré syndrome (GBS) is an acute autoimmune polyradiculoneuropathy with a monophasic course, the development of which takes a maximum of four weeks. Relapse is rare (approximately 3% of cases). As opposed to chronic inflammatory demyelinating polyneuropathy (CIDP), where a link to lymphoma and certain other malignancies has been described, linkage of GBS to cancer is questionable. Nevertheless, several cases occur in the literature describing the occurrence of GBS in patients with malignancies. This case report covers a patient with renal carcinoma who presented with GBS, and possible linkage to malignancy is discussed.

Key words:
Guillain-Barré syndrome – paraneoplastic syndrome – renal carcinoma

Zdroje

1. Graus F, Delattre JY, Antoine JC, Dalmau J, Giometto B, Grisold W et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry 2004; 75(8): 1135–1140.

2. Bednařík J, Voháňka S, Ehler E, Ambler Z, Piťha J, Veckovský J et al. Standard pro léčbu pacientů s autoimunitními nervosvalovými onemocněními intravenózním lidským imunoglobulinem a plazmaferézou. Cesk Slov Neurol N 2010; 73/106(5): 579–589.

3. Vigliani MC, Magistrello M, Polo P, Mutani R, Chiò A. Risk of cancer in patients with Guillain-Barré syndrome (GBS). A population-based study. J Neurol 2004; 251(3): 321–326.

4. Emilia-Romagna Study Group on Clinical and Epidemiological Problems in Neurology. A prospective study on the incidence and prognosis of Guillain--Barré syndrome in Emilia-Romagna region, Italy (1992–1993). Neurology 1997; 48(1): 214–221.

5. Kennedy RH, Danielson MA, Mulder DW, Kurland LT. Guillain-Barré syndrome: a 42-year epidemiologic and clinical study. Mayo Clin Proc 1978; 53(2): 93–99.

6. Halls J, Bredkjaer C, Friis ML. Guillain-Barré syndrome: diagnostic criteria, epidemiology, clinical course and prognosis. Acta Neurol Scand 1988; 78(2): 118–122.

7. Antoine JC, Mosnier JF, Absi L, Convers P, Honnorat J, Michel D. Carcinoma associated paraneoplastic peripheral neuropathies in patients with and without anti-onconeural antibodies. J Neurol Neurosurg Psychiatry 1999; 67(1): 7–14.

8. Viala K, Behin A, Maisonobe T, Leger JM, Stojkovic T, Davi F et al. Neuropathy in lymphoma: a relationship between the pattern of neuropathy, type of lymphoma and prognosis? J Neurol Neurosurg Psychiatry 2008; 79(7): 778–782.

9. Ruts L, Drenthen J, Jacobs B, van Doorn P. Distinguishing acute-onset CIDP from fluctuating Guillain--Barre syndrome: a prospective study. Neurology 2010; 74(21): 1680–1686.

10. Ruts L, van Koningsveld R, van Doorn PA. Distinguishing acute-onset CIDP from Guillain-Barré syndrome with treatment related fluctuations. Neurology 2005; 65(1): 138–140.

11. Hantson P, Kevers L, Fabien N, Van Den Bergh P. Acute-onset chronic inflammatory demyelinating polyneuropathy with cranial nerve involvement, dysautonomia, respiratory failure, and autoantibodies. Muscle Nerve 2010; 41(3): 423–426.

12. Comi C, Osio M, Ferretti M, Mesturini R, Cappellano G, Chiocchetti A et al. Defective Fas-mediated T-cell apoptosis predicts acute onset CIDP. J Peripher Nerv Syst 2009; 14(2): 101–106.

13. Latov N. Pathogenesis and therapy of neuropathies associated with monoclonalgammopathies. Ann Neurol 1995; 37 (Suppl 1): S32–S42.